Clinical Trial Update: This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the reversal agent idarucizumab in patients on dabigatran requiring emergency surgery or experiencing bleeding has completed and posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage

Drugs mentioned

• Dabigatran (Dabigatran etexilate)
• Idarucizumab (idarucizumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hemorrhage | Phase 3 | Status: COMPLETED | Results posted: 2021-08-20